Peptide Comparison
Substance P AntagonistsvsKPV (Alpha-MSH Fragment)
NK1 receptor blockers that reduce pain signals and nausea at the source
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
At a Glance
Quick
comparison
Dose Range
Substance P Antagonists
80 mg–125 mg mg
KPV (Alpha-MSH Fragment)
200 mcg–1500 mcg mcg
Frequency
Substance P Antagonists
Once daily
KPV (Alpha-MSH Fragment)
Once daily
Administration
Substance P Antagonists
Oral capsule
KPV (Alpha-MSH Fragment)
Oral
Cycle Length
Substance P Antagonists
Ongoing/indefinite
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
Onset Speed
Substance P Antagonists
Moderate (1-2 weeks)
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
Evidence Level
Substance P Antagonists
Moderate human trials (Phase 1-2)
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Anti-Nausea & Antiemetic
Pain Modulation
Neuroprotection
Anti-Inflammatory
Gut Health
Healing & Recovery
Technical Data
Compound
specifications
Substance P Antagonists
Molecular Formula
C23H21F7N4O3
Molecular Weight
534.4 g/mol
Half-Life
9-13 hours (elimination half-life)
Bioavailability
Approximately 60-65% oral bioavailability; food may increase absorption
CAS Number
170729-80-3
KPV (Alpha-MSH Fragment)
Molecular Formula
C16H30N4O4
Molecular Weight
342.43 Da
Half-Life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS Number
67727-97-3
Applications
Best
suited for
Substance P Antagonists
Managing severe nausea from cancer treatments
Substance P Antagonists is particularly well-suited for individuals focused on managing severe nausea from cancer treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic pain reduction
Substance P Antagonists is particularly well-suited for individuals focused on chronic pain reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving quality of life during intensive medical therapy
Substance P Antagonists is particularly well-suited for individuals focused on improving quality of life during intensive medical therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Substance P Antagonists
Common
- Headache
- Fatigue or weakness
- Constipation
Uncommon
- Loss of appetite
- Dizziness
Serious
- Stevens-Johnson Syndrome (SJS)
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Research Status
Safety
& evidence
Substance P Antagonists
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for this use
Safety Overview
Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients.
Contraindications
- xSevere hypersensitivity to aprepitant or any component
- xConcurrent use with certain other medications that affect the liver
- xSevere cardiac conditions
KPV (Alpha-MSH Fragment)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- xNot approved for human clinical use
- xUnknown interactions with immunosuppressive medications
- xInsufficient safety data for pregnancy and lactation
- xPotential melanocortin receptor effects in susceptible individuals
Decision Guide
Which is
right for you?
Choose Substance P Antagonists if...
- Managing severe nausea from cancer treatments
- Chronic pain reduction
- Improving quality of life during intensive medical therapy
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies